Navigation Links
Pharmacyclics Announces Appointment of New Management Team and Board Director to Accelerate Its Future Growth
Date:2/12/2009

ef="http://www.pharmacyclics.com" target="_new">http://www.pharmacyclics.com.

NOTE: Other than statements of historical fact, the statements made in this press release about future plans for and the timing of initiation of our clinical trials, progress of and reports of results from preclinical and clinical studies, expected effect of our products under development, clinical development plans and product development and corporate partnering activities are forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. The words "project," "believe," "will," "may," "continue," "plan," "expect," "intend," "anticipate," variations of such words, and similar expressions also identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. The forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that may cause actual results to differ materially from those in the forward-looking statements. Factors that could affect actual results include risks associated with unexpected delays in clinical trials and preclinical studies and the timing for making related regulatory filings; the fact that data from preclinical studies and Phase 1 or Phase 2 clinical trials may not necessarily be indicative of future clinical trial results; our ability to obtain future financing and fund the product development of our pipeline; the initiation, timing, design, enrollment and cost of clinical trials and preclinical studies; our ability to establish successful partnerships and collaborations with third parties; the regulatory approval process in the United States and other countries; and our future capital requirements. For further information about these risks and other factors that may affect the actual results achieved by Pharmacyclics, please see the company's reports as filed with the U.S. Securities and Exchan
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Pharmacyclics Secures $5.0 Million in Debt Financing
2. Pharmacyclics Reports First Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Reports Fourth Quarter and Fiscal 2008 Financial Results
4. Pharmacyclics Announces It Received Nasdaq Notice of Compliance
5. Pharmacyclics Announces It Received Nasdaq Notification
6. Pharmacyclics Announces Multiple Presentations at the American Association for Cancer Research Annual Meeting
7. Savient Announces Appointment of David Gionco as Chief Financial Officer
8. Vermillion Announces Notice of Issuance of U.S. Patent Covering Hepcidin as a Biomarker for Ovarian Cancer
9. SENOMYX ANNOUNCES FOURTH QUARTER AND YEAR-END 2008 FINANCIAL RESULTS
10. Genesis Pharmaceuticals Announces Conference Call to Discuss Results for its Second Quarter of FY 2009
11. Cord Blood Announces $1 Million Reduction in Long Term Debt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Ouagadougou, Burkina Faso (PRWEB) July 10, 2014 ... Burkina Faso, today have access to an additional ... to increase access to contraception at all levels ... combining a lower-dose formulation of a widely used ... injection system. , Burkina Faso is the first ...
(Date:7/10/2014)... 2014 Deep Knowledge Ventures last ... on ‘Commercialising Longevity Research’ and welcomed a host ... London Bioscience Innovation Center for the event, organised ... Analytics Ltd. The meeting highlighted the need for ... for age-related disease, as well as the crucial ...
(Date:7/10/2014)... Boston, Mass. (PRWEB) July 10, 2014 ... , today announced that Alan Swahn, a former vice ... Terascala’s executive team as vice president of marketing. Terascala’s ... from Dell and NetApp create the highest performance and ... has been appointed to guide Terascala’s channel expansion and ...
(Date:7/10/2014)... July 10, 2014 Robert Harman, DVM, Founder ... company, is proud to announce the relaunch of his highly ... a new series called “ What are Stem Cells ?” ... honest and straightforward foundation in the basics of stem cell ... on the right type of treatment when considering regenerative medicine. ...
Breaking Biology Technology:Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 2Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 3Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 4Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 5Injectable Contraceptive Launched in Burkina Faso to Expand Choice and Address Unmet Need 6DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 2DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 3DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 4DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 5DKV Sponsors Forum on Commercialising Longevity Research; Brings Together Scientists, Investors, Entrepreneurs and Celebrities 6Terascala Expands Executive Team 2Terascala Expands Executive Team 3Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 2Robert Harman, DVM Talks About What Stem Cells are in His Latest Blog Series for Vet-Stem, Inc. 3
... Thieme's new book, Islands in the Clickstream is ... WTN will be reprinting excerpts from selected chapters of Islands ... week features an excerpt from chapter four, Hacking and the ... of Thieme's writings. , , Hactivism and Soul Power ...
... this summer, we looked at venture capital funding in ... reached about $5 billion in investments in small companies. ... $5.4 billion invested during the fourth quarter of 2003, ... results for the second quarter of 2004 were a ...
... Source: Office of U.S. Rep. Jane Harman (D-Redondo Beach, Calif.) ... Republican? , ,As silly as that question is, it appears ... lamentable wedge issues of the 2004 presidential campaign. Both political ... a back seat to stem cell politics. , ,If you ...
Cached Biology Technology:Islands in the Clickstream: Hactivism and Soul Power 2Islands in the Clickstream: Hactivism and Soul Power 3Islands in the Clickstream: Hactivism and Soul Power 4Midwest life science companies capture 3% of VC investments in Q.2 2Dividing stem cells along partisan lines isnt a good experiment 2Dividing stem cells along partisan lines isnt a good experiment 3
(Date:7/13/2014)... New research raises the prospect of more effective ... muscle occurring in about half of all cancer patients, ... Dana-Farber Cancer Institute. , Many strategies have been tried ... that patients can,t endure potentially life-saving treatments, but none ... July 13 advanced online edition of Nature , ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... of Entiat on Tuesday, July 8, 2014. Despite the ... over 1,000 acres by evening. Three outbuildings were damaged. ... the Washington Department of Natural Resources. The fire ... fire control strategies and tactics. Other cooperators include the ... Resources, (WA DNR), Bureau of Land Management, Chelan County ...
Breaking Biology News(10 mins):Antibody halts cancer-related wasting condition 2Antibody halts cancer-related wasting condition 3ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... time that exercise induces neurogenesis in a specific brain ... mechanism was not fully understood. The hippocampus plays an ... one of the brain regions where new neurons are ... maturation , The researchers demonstrated that mice with ...
... turtles are benefiting from marine protected areas by using habitats ... study that is the first to track the federally protected ... listed as endangered in Florida and threatened throughout the rest ... after their forays to nest on beaches in the Southeast ...
... PHILADELPHIAA new study looking at the genomes of more ... with an increased risk of testicular cancer, the most ... from this first-of-its-kind meta-analysis were reported online May 12 ... Perelman School of Medicine at the University of ...
Cached Biology News:Serotonin mediates exercise-induced generation of new neurons 2Sea turtles benefiting from protected areas 2Sea turtles benefiting from protected areas 3Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer 2Penn Medicine researchers identify 4 new genetic risk factors for testicular cancer 3
Direct ELISA Assay Diluent - EDTA, 10 L...
... Immunogen: Synthetic peptide derived from ... junctophilin-3. Specificity: Specific for the ... Reactivity: Mouse (positive controls: mouse ... heart tissues). Applications: Western blotting ...
... agarose gel electrophoresis into an automated, high-throughput ... bufferless, pre-cast system is ideal for analyzing ... and more. Fully automated, robot-compatible, and ready ... system makes your high-throughput screening assignments as ...
...
Biology Products: